SCHEMBL6996548

SCHEMBL6996548

CCOC(=O)c1cc(C)c(CC[C@@H](O)CO)s1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
KDM4E B2RXH2 4/20 0.37
ALDH1A1 P00352 3/20 0.37
TDP1 Q9NUW8 3/20 0.37
HPGD P15428 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
MAPK14 Q16539 1/20 0.36
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HTT P42858 1/20 0.36
MAPT P10636 5/20 0.36
GAA P10253 4/20 0.36
ATM Q13315 2/20 0.36
GLA P06280 1/20 0.36
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8362199 1.00 HDAC3 (0.40) HDAC3HDAC4HDAC1HDAC6KDM4E
SCHEMBL7836985 0.88 CSNK2A2 (0.36) HDAC3KDM4EALDH1A1HPGDL3MBTL1
SCHEMBL6999104 0.83 DAO (0.46) KDM4EALDH1A1HPGDL3MBTL1NPC1
SCHEMBL6990188 0.81 HDAC3 (0.36) HDAC3HDAC4HDAC1HDAC6KDM4E
SCHEMBL6990186 0.81 HDAC3 (0.36) HDAC3HDAC4HDAC1HDAC6KDM4E
SCHEMBL6999078 0.80 HDAC3 (0.35) HDAC3HDAC4HDAC1HDAC6KDM4E
SCHEMBL6999081 0.80 HDAC3 (0.35) HDAC3HDAC4HDAC1HDAC6KDM4E
SCHEMBL6998895 0.80 SERPINE1 (0.38) HDAC3HDAC4HDAC1HDAC6KDM4E
SCHEMBL7000933 0.80 SERPINE1 (0.38) HDAC3HDAC4HDAC1HDAC6KDM4E
SCHEMBL6998902 0.80 SERPINE1 (0.38) HDAC3HDAC4HDAC1HDAC6KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0846111-B1 SYNTHESES OF OPTICALLY PURE COMPOUNDS USEFUL AS GARFT INHIBITORS AND THEIR INTERMEDIATES AGOURON PHARMA (US) 2003-08-27 EP disclosed
US-5981748-A Synthesis of optically pure compounds useful as GARFT inhibitors and their intermediates AGOURON PHARMACEUTICALS, INC. (US) 1999-11-09 US disclosed
EP-0846111-A1 SYNTHESES OF OPTICALLY PURE COMPOUNDS USEFUL AS GARFT INHIBITORS AND THEIR INTERMEDIATES AGOURON PHARMACEUTICALS, INC. (US) 1998-06-10 EP disclosed
WO-1996040674-A1 SYNTHESES OF OPTICALLY PURE COMPOUNDS USEFUL AS GARFT INHIBITORS AND THEIR INTERMEDIATES AGOURON PHARMACEUTICALS, INC. (US) 1996-12-19 WO disclosed